Though multiple randomized clinical trials have demonstrated the efficacy of the combination of ICPIs like PD1/PD-L1 inhibitors and anti-CTLA4 monoclonal antibodies along with chemotherapy in the first-line treatment as well as maintenance therapy of ES-SCLC, their practical perquisite in SCLC still remains under speculation. Here, CD274 is linked to small cell lung carcinoma.